ATUM

Reimagining the Translation from Biologics Discovery to Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, April 18, 2024
ATUM, Immortalised cell line, ChromeOS, Machine learning, Doctor of Philosophy, SBCS, Biology, SBC, Business

TORONTO, April 18, 2024 /PRNewswire-PRWeb/ -- Traditionally, the journey from biologics discovery to their development and initial human trials has followed a familiar route, sticking to established norms. It is now more vital than ever for biologics developers to obtain access to the most effective tools, technologies and machine learning strategies to mitigate hurdles during the scaling-up process.

Key Points: 
  • In this free webinar, gain insights into the most effective tools, technologies and strategies for biologics discovery and development.
  • The featured speakers will share insights into better alignment between biotechs and service providers (CROs and CDMOs) to bridge the translation from preclinical to clinical development more effectively.
  • TORONTO, April 18, 2024 /PRNewswire-PRWeb/ -- Traditionally, the journey from biologics discovery to their development and initial human trials has followed a familiar route, sticking to established norms.
  • Register for this webinar today to gain insights into the most effective tools, technologies and strategies for biologics discovery and development.

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Retrieved on: 
Thursday, February 29, 2024
Investigational New Drug, CRL, Charles River Laboratories, LEAP, Entrepreneurship, OK, ATUM, Chemistry, CDMO, Safety, CHO, CGMP, Organization, Portable, Control, IND, CMC, Partnership, Pharmaceutical industry

The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.

Key Points: 
  • The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.
  • Combining Charles River's industry-leading experience in antibody discovery services, safety, and analytics with Wheeler's Portable CMC® platform will accelerate therapeutic discovery to Investigational New Drug (IND) submission timelines.
  • Wheeler Bio's mission is to solve translational challenges inherent in advancing from discovery to CMC development and early-clinical trial material supply.
  • Jesse McCool, CEO and Co-Founder of Wheeler Bio, stated, "Wheeler is excited to expand our relationship with Charles River and to link with their discovery organization.

Quantifying Genetic Stability and Quality Control of Multiple Integrations of Orthogonal Transposases, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 25, 2023
Business development, LEAP, NGS, CHO, ATUM, Doctor of Philosophy, Gene, Metabolism, TLA, Vaccine

TORONTO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into transposase-mediated genome engineering, genetic quality control (QC) and stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology. Genes encoding biotherapeutic proteins can stably be introduced into mammalian genomes by several different approaches. The transposon-based platform avoids major challenges presented by random integration or viral-based delivery systems.

Key Points: 
  • In this free webinar, learn about transposase-mediated genome engineering, genetic quality control and ensuring the genetic stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology.
  • TORONTO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into transposase-mediated genome engineering, genetic quality control (QC) and stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology.
  • Furthermore, by comparing the TLA data of different timepoints they were able to evaluate the genetic stability and integrity of the transposons.
  • Join this webinar to learn about transposase-mediated genome engineering, genetic quality control and ensuring the genetic stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology.

ATUM Partners with Anagram Therapeutics to Extend Collaboration to Develop Orally Delivered Enzyme Therapies for Malabsorption and Nutrient Metabolism Disorders

Retrieved on: 
Wednesday, October 4, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Anagram, Partnership, EPI, GPS, Therapy, Fats, Digestion, Malnutrition, Enzyme, Quality of life, Cystic fibrosis, Absorption, Biomarker, Life expectancy, Trial of the century, Plasma, Machine learning, Malabsorption, Enzyme replacement therapy, Safety, Pharmaceutical industry, ATUM

"We are excited by the initiation of the ANG003 clinical study, an enzyme replacement therapy engineered using our multidimensional optimization GPS platform," said Claes Gustafsson, Chief Commercial Officer at ATUM.

Key Points: 
  • "We are excited by the initiation of the ANG003 clinical study, an enzyme replacement therapy engineered using our multidimensional optimization GPS platform," said Claes Gustafsson, Chief Commercial Officer at ATUM.
  • It has been an honor to work closely with the Anagram team to harness this technology for the purpose of addressing malabsorption and nutrient metabolism disorders."
  • The study design includes up to four possible combinations of orally delivered lipase, protease, and amylase administered with a test meal.
  • “Initiating this clinical study and dosing the first patient is a significant milestone, as we continue to evolve orally delivered enzymes as therapeutics for malabsorption and nutrient metabolism disorders.”

ATUM Awarded EcoVadis Silver Medal Rating for its Sustainability Performance

Retrieved on: 
Thursday, September 14, 2023
Biotechnology, Health, Science, Other Science, Research, ISO, Facility, Silver medal, Carbon, Targets, Office of Scientific Research and Development, International Training Centre of the International Labour Organization, ILO, Development, Ten Principles for the Establishment of a Monolithic Ideological System, United Nations Global Compact, Sustainability, GRI, Sustainable procurement, Biophysical environment, ESG, Environment, International Labour Organization, Social, Milan Puskar Health Right, Scientific method, Labour, Renewable energy, ATUM, Ethics

ATUM, a global specialist and industry leader in bioengineering solutions, today announced that it has been awarded the prestigious Silver Medal rating from EcoVadis, the world’s most trusted provider of business sustainability ratings.

Key Points: 
  • ATUM, a global specialist and industry leader in bioengineering solutions, today announced that it has been awarded the prestigious Silver Medal rating from EcoVadis, the world’s most trusted provider of business sustainability ratings.
  • This milestone is the first year ATUM has been recognized by EcoVadis and places the company in the top 15% (85th percentile) of companies rated by EcoVadis in the Scientific Research and Development industry.
  • Among all companies rated by EcoVadis, ATUM ranks at the 74th percentile globally.
  • “At ATUM, we are immensely proud to be recognized with the EcoVadis Silver Medal rating, which underscores our unwavering dedication to sustainability, diversity, equity, and business ethics,” said Jeremy Minshull, Ph.D., Chief Executive Officer of ATUM.

Utilizing AI to Engineer Biologics: From Discovery to Manufacturing, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, July 26, 2023
Computational biology, DNA, Therapy, Telephone numbers in Hungary, ATUM, Biomedical engineering, Machine learning, Algorithm, Engineering, Drug discovery, Protein engineering, Artificial intelligence, Entrepreneurship, CIO, AI, Synthetic biology, Medical device, Pharmaceutical industry

TORONTO, July 26, 2023 /PRNewswire-PRWeb/ -- In an age where biotechnological advances continue to push the boundaries of scientific discovery, the application of artificial intelligence (AI) in engineering of biologics has emerged as a promising frontier. The webinar is particularly well suited for professionals in the fields of protein engineering, biomedical engineering, drug discovery, bioinformatics, computational biology, pharmaceutical and biotechnology manufacturing, and synthetic biology.

Key Points: 
  • In this free webinar, learn about using AI and machine learning in the engineering of biologics, from discovery to manufacturing.
  • The featured speaker will discuss the integration of machine learning tools and empirical measurement in a unique protein engineering platform.
  • Mark your calendars for this insightful live webinar "Utilizing AI to Engineer Biologics: From Discovery to Manufacturing" taking place on Tuesday, August 15, 2023, at 10am PDT (1pm EDT).
  • The hour-long session promises to be a riveting exploration of AI applications in biologics engineering, an indispensable area of contemporary scientific research.

Wheeler Bio and Charles River Laboratories Announce Agreement to Build and Operate RightSource(SM) Laboratory

Retrieved on: 
Wednesday, May 31, 2023
LEAP, QC, Portable, CMC, ATUM, CDMO, Ban Sop Ruak, CGMP, Quality control, Entrepreneurship, CRL, IND, NYSE, Fine chemical

OKLAHOMA CITY, May 31, 2023 /PRNewswire/ -- Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), and Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement to implement RightSourceSM at Wheeler Bio's current good manufacturing practice (cGMP) biologics manufacturing facility in Oklahoma City, OK. Deployed on-site at a client's facility, RightSourceSM is a flexible biologics testing lab operated and managed by Charles River, making fast, reliable quality control (QC) more accessible to a broader reach of companies like Wheeler Bio.

Key Points: 
  • OKLAHOMA CITY, May 31, 2023 /PRNewswire/ -- Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), and Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement to implement RightSourceSM at Wheeler Bio's current good manufacturing practice (cGMP) biologics manufacturing facility in Oklahoma City, OK.
  • Deployed on-site at a client's facility, RightSourceSM is a flexible biologics testing lab operated and managed by Charles River, making fast, reliable quality control (QC) more accessible to a broader reach of companies like Wheeler Bio.
  • Wheeler Bio and Charles River will work in close collaboration to set up a cGMP testing lab at Wheeler Bio's ultra-modern Oklahoma City facility .
  • The RightSourceSM Laboratory at Wheeler Bio will be operational in Q3 2023 and is anticipated to start in-process and release testing by Q4 2023.

ATUM Announces Leap-In Transposase® Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based Therapeutics

Retrieved on: 
Tuesday, January 24, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Engineering, Doctor of Philosophy, LEAP, Algorithm, Exosome, Immortalised cell line, Genome, Vaccine, ATUM

ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In Transposase® technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.

Key Points: 
  • ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In Transposase® technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.
  • Under the terms of the agreement, ATUM will provide Codiak access to its Leap-In Transposase® technology to generate mammalian cells expressing exosomes engineered to deliver therapeutic payloads.
  • The Leap-In technology is an integrated solution combining proprietary re-coding algorithms, unique genetic vector elements as well as a transposon-based mechanism for efficient insertion of genetically stable elements into the genome.
  • We are proud and excited to license the Leap-In Transposase® technology to Codiak for the engineering of cell lines that enables rapid and robust production of exosomes.”

Wheeler Bio Licenses ATUM's Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering

Retrieved on: 
Wednesday, November 30, 2022
The Leap, Culture, OKC, Engineering, Cros, DNA, ATUM, CMC, IND, Partnership, Process, Wheeler, CGMP, File, Technology transfer, Drug development, Biology, LEAP, Translation, Business, CDMO, Drug discovery, Micah, Fine chemical, Vaccine

Wheeler Bio believes these lifecycle challenges can be reduced with access to industry-leading technologies and democratization of standardized manufacturing platforms.

Key Points: 
  • Wheeler Bio believes these lifecycle challenges can be reduced with access to industry-leading technologies and democratization of standardized manufacturing platforms.
  • Jesse McCool, Ph.D., Founder and Chief Executive Officer at Wheeler Bio, said, "We are very excited to license the Leap-In Transposase technology and the miCHO cell line.
  • Wheeler Bio will incorporate the Leap-In Transposase technology into its state-of-the-art cell line development platform, including an option for clients to utilize the miCHO cell line.
  • Join the Wheeler Bio community by visiting www.wheelerbio.com , following Wheeler Bio on LinkedIn , or scheduling a chat with Wheeler's co-founder and CEO at wheeler.com/ceo .

Professor Horowitz of Stanford University Recognized with ACM/IEEE CS Eckert-Mauchly Award

Retrieved on: 
Thursday, June 16, 2022
CMOS, Association, ATUM, Memory, Method, Fred Brooks, Technology, DRAM, View, DASH, Efficiency, Student, IEEE Computer Society, Research, Engineering, Future, Eckert–Mauchly Award, ISCA, Computer, Dennard scaling, ENIAC, Stanford University, IEEE CS, ACM Fellow, Directory, LPDDR, LOS, Architecture, IEEE, Multimedia, Collection, Computer science, Electrical engineering, Rambus, Computer architecture, ACM, FLASH, Consumer electronics, Video game console, Computer data storage

LOS ALAMITOS, Calif., June 16, 2022 /PRNewswire/ -- The IEEE Computer Society (IEEE CS) and the Association for Computing Machinery (ACM) have named Professor Mark Horowitz as the 2022 recipient of the ACM/IEEE CS Eckert-Mauchly Award.  An IEEE and ACM Fellow, Horowitz is a professor with a joint appointment in the Departments of Electrical Engineering and Computer Science at Stanford University, and is being recognized "for contributions to microprocessor memory systems." 

Key Points: 
  • LOS ALAMITOS, Calif., June 16, 2022 /PRNewswire/ -- The IEEE Computer Society (IEEE CS) and the Association for Computing Machinery (ACM) have named Professor Mark Horowitz as the 2022 recipient of the ACM/IEEE CS Eckert-Mauchly Award.
  • An IEEE and ACM Fellow, Horowitz is a professor with a joint appointment in the Departments of Electrical Engineering and Computer Science at Stanford University, and is being recognized "for contributions to microprocessor memory systems."
  • Prof. Horowitz has made numerous contributions to computer architecture and to the architecture of computer memory systems.
  • Horowitz will receive the Eckert-Mauchly Award during the ACM/IEEE International Symposium on Computer Architecture( ISCA ), to be held in New York City, June 18t 22.